Drug Profile

Research programme: Alzheimer's disease therapeutics - Collaborations Pharmaceuticals

Latest Information Update: 30 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Collaborations Pharmaceuticals
Class Antidementias
Mechanism of Action Acetylcholinesterase inhibitors; Glycogen synthase kinase 3 beta inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

30 Apr 2024 Preclinical development is ongoing in USA for Alzheimer's-disease (Collaborations Pharmaceuticals pipeline, April 2024)
28 Feb 2024 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
27 Aug 2019 Research programme: Alzheimer's disease therapeutics is available for licensing as of 27 Aug 2019. http://www.collaborationspharma.com/pipeline

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com